Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus gefitinib for T790M-positive non-small cell lung cancer after prior gefitinib
ChiCTR1800014428Phase 4Recruiting
- Sponsor
- Xijing Hospital
- Start
- Jan 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib and gefitinib in non-small cell lung cancer (NSCLC), sponsored by Xijing Hospital. Primary endpoint: progression-free survival. Started Jan 2018; status: recruiting.
02
Drugs
Rivoceranibgefitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1800014428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014428.